The U.S. FDA is expediting the development of new mental illness treatments by awarding priority review vouchers to three companies researching psychedelic drugs, following a directive from President Trump. Compass Pathways, Usona Institute, and Transcend Therapeutics are involved in the development of psilocybin and methylone-based therapies.
The United States Food and Drug Administration ( FDA ) has taken a significant step towards accelerating the availability of novel treatments for severe mental health conditions.
This action follows a recent executive order issued by former President Donald Trump, aimed at streamlining the approval process for psychedelic drugs demonstrating breakthrough therapy potential. The FDA has awarded priority review vouchers to three companies currently engaged in the development of these innovative therapies.
These vouchers represent a substantial benefit, potentially reducing the standard FDA review timeline from a typical six to ten months to as little as one to two months, significantly expediting the path to market for these potentially life-changing medications. Compass Pathways, a leading company in the field of psychedelic-assisted therapy, has publicly confirmed its receipt of a priority review voucher for COMP360, its synthetic psilocybin formulation designed to treat individuals suffering from treatment-resistant depression.
This confirmation underscores the progress being made in harnessing the therapeutic potential of psilocybin, a naturally occurring psychedelic compound found in certain mushrooms. While the FDA has identified the other two recipient companies, their identities remain somewhat obscured. One is actively investigating psilocybin's efficacy in addressing major depressive disorder, while the other is exploring the use of methylone, a synthetic cathinone, as a treatment for post-traumatic stress disorder (PTSD).
Usona Institute and Transcend Therapeutics are the companies developing these respective treatments, but have not yet officially confirmed their voucher awards. Attempts to obtain confirmation from the Department of Health and Human Services have also been unsuccessful, leaving a degree of uncertainty surrounding their involvement.
Compass Pathways CEO Kabir Nath recently indicated the company is preparing for a potential launch by the end of the current year, viewing the priority voucher as a positive, albeit not transformative, development in their approval trajectory. The company’s stock experienced a modest increase following the announcement, reflecting investor confidence in the accelerated review process. The need for more effective mental health treatments is paramount, with statistics revealing a substantial prevalence of mental illness within the U.S. population.
Data from the National Alliance on Mental Illness indicates that 23.4% of U.S. adults were affected by mental illness in 2024, and a concerning 17.6% of veterans experienced similar challenges in 2023. The underlying mechanism of action for these psychedelic treatments centers around their ability to activate specific proteins located on the surface of nerve cells.
These proteins play a crucial role in regulating the brain’s neuroplasticity – its capacity to reorganize itself by forming new neural connections and repairing damaged circuits. This enhanced neuroplasticity is believed to be key to the therapeutic effects observed in patients undergoing psychedelic-assisted therapy.
However, it is important to acknowledge that these treatments are not without potential risks. During the administration of psychedelic medications, patients may experience acute anxiety, panic attacks, or confusion.
Therefore, careful monitoring and a supportive therapeutic environment are essential components of safe and effective treatment. Interestingly, despite former President Trump’s expressed support for ibogaine, a psychoactive substance derived from an African shrub, the FDA did not include it among the drugs receiving priority vouchers. This decision likely reflects the relatively less advanced clinical development of ibogaine compared to psilocybin.
Nevertheless, the FDA is permitting an early-stage clinical trial of a derivative of ibogaine, developed by DemeRx NB, as a potential treatment for alcohol-use disorder, indicating continued interest in exploring its therapeutic possibilities. Experts suggest that the FDA’s current focus on psilocybin is a direct result of its more mature clinical profile and the accumulating evidence supporting its efficacy.
Michael Thase, a professor of psychiatry, posits that ibogaine may reach a similar level of clinical advancement in the near future, potentially becoming eligible for priority review in the coming year. This move by the FDA signals a significant shift in the approach to mental health treatment, embracing innovative therapies and prioritizing the development of solutions for conditions that have long been underserved
FDA Psychedelic Drugs Mental Health Psilocybin Priority Review Voucher Treatment-Resistant Depression PTSD COMP360 Compass Pathways Usona Institute Transcend Therapeutics
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA grants quick review for 3 psychedelic drug trialsErika Edwards is a health and medical news writer and reporter for NBC News and 'TODAY.'
Read more »
FDA: Three psychedelic drugs to get review following Trump directiveThe Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including depression. The agency announced the move Friday, several days after President Donald Trump signed an executive order calling to speed up access to the mind-altering drugs.
Read more »
FDA plans ultra-fast review of three psychedelic drugs following Trump directiveThe Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including depression.
Read more »
FDA fast-tracks psychedelic drug research following Trump executive orderThe FDA's Marty Makary fast-tracked research for three companies to make psychedelic treatments for mental illness.
Read more »
FDA plans ultra-fast review of three psychedelic drugs following Trump directiveThe move reflects growing popular support for the mind-altering substances among Trump’s supporters, including combat veterans and followers of the Make America Healthy Again movement.
Read more »
FDA plans ultra-fast review of three psychedelic drugs following Trump directiveThe Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including major depression.
Read more »